Petefészekrák: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• BRCA1 20
• BRCA2 13
• PARP 27
• TP53 6
• PD-1 12
• AKT 2
• HER2 16
• PD-L1 7
• PI3K 3
• STAT3 1
• mTOR 0
• VEGF 7
• KRAS 6
• EGFR 3
• PTEN 2
• MAPK 0
• CTNNB1 0
• FAK 1
• MYC 0
• NRF2 0
• CTLA-4 6
• ERK 1
• JAK 0
• STING 0
• GPX4 0
• HIF-1 0
• MEK 1
• TROP2 4
• PALB2 5
• B7-H3 7
• CDK4/6 4
• ATM 1
• CD47 0
• IL-6 0
• PIK3CA 3
• EZH2 1
• JNK 0
• YAP 0
• BCL-2 0
• BRAF 4
• CXCR4 0
• HDAC 0
• PPAR 0
• AMPK 0
• ARID1A 3
• AXL 1
• COX-2 2
• NMDA 0
• TIGIT 0
• AR 0
• CD40 1
• HER3 1
• HMGB1 0
• KEAP1 1
• METTL3 0
• RAS 0
• TLR4 0
• FGFR 0
• PINK1 0
• PKM2 0

1+ intézményből 1, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · F31

  The role of p16 expression in sensitivity and resistance to CDK2 inhibitors

  University of Colorado· Boulder, Egyesült Államok· 43 146 USD awarded in fiscal year 2026· until 2029. szept.

• NIH NIAID · R56

  Functional dissection of a novel E2 complex critical for the HPV16 life cycle

  Virginia Commonwealth University· Richmond, Egyesült Államok· 768 308 USD awarded in fiscal year 2026· until 2027. aug.

• NIH NCI · R01

  Overcoming ovarian cancer chemoresistance by co-targeting senescence and apoptosis

  Harvard University D/B/A Harvard School of Public Health· Boston, Egyesült Államok· 390 447 USD awarded in fiscal year 2026· until 2031. aug.

• NIH NCI · R01

  Immune Dysfunction, Social Determinants of Health, and Ovarian Cancer Outcome Differences

  University of Pittsburgh at Pittsburgh· Pittsburgh, Egyesült Államok· 674 142 USD awarded in fiscal year 2026· until 2031. aug.

• NIH NICHD · R61

  Ultrasound-guided Ovarian Tissue Graft generation Platform to improve fertility outcomes

  Atera Medical· Mountain View, Egyesült Államok· 377 257 USD awarded in fiscal year 2026· until 2028. jún.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Decoding the Lipidome of Adipose-Derived Extracellular Vesicles in Ovarian Cancer: Mechanistic Insight into Tumor-Adipose Crosstalk (Lipid-Ex)

  Philipps Universitaet Marburg· Marburg, Németország· EU contribution 202 125 EUR· until 2028. dec.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Precision Reasoning In Multimodal Ovarian cancer (PRIMO)

  Institut Regional du Cancer de Montpellier· Montpellier Cedex 5, Franciaország· EU contribution 150 000 EUR· until 2028. jún.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  CAR T ceLls with Anti-exhaUstion Device for Immunotherapy Advancement (CLAUDIA)

  Fondazione Istituto Italiano di Tecnologia· Genova, Olaszország· EU contribution 150 000 EUR· until 2028. márc.

• European Commission (Horizon Europe) · HORIZON-EIC

  Interpretable Multimodal Predictive Agents and Digital Twins for Ovarian Cancer (IMPACT-OC)

  Danube Private University Gmbh· Krems-Stein, Ausztria· EU contribution 3 977 586 EUR· until 2030. szept.· 5 countries

• European Commission (Horizon Europe) · HORIZON-RIA

  A Novel Phase-2a Clinical Trial for a Next-Generation Oncolytic Immunotherapy Targeting Platinum-Resistant Ovarian Cancer (OCTOPOD-Ph2a)

  Theolytics Ltd· Oxford, Egyesült Királyság· EU contribution 7 998 791 EUR· until 2029. máj.· 3 countries

10 of 662 running projects, newest first. Listed amounts together: 367,4 M USD + 54,2 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

Ebben a nézetben egy vizsgálat sem jelzi, hogy megosztaná a résztvevői adatokat.

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 48
• Organoids 19
• Mendelian Randomization Analysis 30
• CRISPR-Cas Systems 15
• Gene Expression Profiling 126
• Sequence Analysis, RNA 11
• Whole Genome Sequencing 6
• Exome Sequencing 11
• Proteomics 62
• Metabolomics 17
• Mass Spectrometry 6
• Flow Cytometry 26
• Immunohistochemistry 95
• Liquid Biopsy 15
• Circulating Tumor DNA 14
• Xenograft Model Antitumor Assays 234
• Positron-Emission Tomography 9
• Magnetic Resonance Imaging 57
• Machine Learning 60
• Deep Learning 36
• Cohort Studies 105
• Genome-Wide Association Study 27

• [Oncogenetics and molecular tumor boards in private practice: Specificities and perspectives].

  Bull Cancer, 2026. szept.

• Beyond CA-125: circulating cell-free DNA as the next-generation biomarker in ovarian malignancy.

  BMC Cancer, 2026. szept.

• Molecular Response Assessment From Circulating Tumor DNA in Patients With Ovarian Cancer Treated With the WEE1 Inhibitor Azenosertib.

  JCO Precis Oncol, 2026. aug.

• Pamiparib plus surufatinib with ctDNA monitoring in platinum-resistant ovarian cancer after PARP inhibitor progression: a phase Ib/II trial (POST-PARPi).

  BMC Med, 2026. aug.

• Current Advances of Molecular Biomarkers and Liquid Biopsies Techniques in Ovarian Cancer.

  Cancer Med, 2026. aug.

• Circulating Tumor DNA in Tracking Minimal Residual Disease and Recurrence in Ovarian Cancer: A Retrospective Cohort.

  Cancer Invest, 2026. máj.

• Pan-Cancer Pre-Treatment ctDNA Detection Using a Highly Sensitive Tumor-Informed Assay.

  Int J Mol Sci, 2026. ápr.

• Prognostic value of circulating tumor DNA for minimal residual disease detection in ovarian cancer: A systematic review and meta-analysis.

  Crit Rev Oncol Hematol, 2026. márc.

• ctDNA monitoring using tumor-informed copy number analysis.

  EMBO Mol Med, 2026. márc.

• Multimodal tumor-agnostic ctDNA analysis for minimal residual disease detection and risk stratification in ovarian cancer: results from the MITO16a/MaNGO-OV2 trial.

  ESMO Open, 2026. febr.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.